GOSS Gossamer Bio, Inc.

NASDAQ
$11.28

Gossamer Bio, Inc. (GOSS) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $4.81 per share.

Gossamer Bio Beat Consensus Estimates
Tuesday, November 10, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Nov 4
Wednesday · 4:00 PM ET
Earnings Whisper
-
vs ($4.81)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $11.33

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Gossamer Bio, Inc.

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and oncology. The company's product pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program which are in clinical stage. Gossamer Bio Inc. is based in San Diego, California.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.